iCare Screening Solution instantly detects early signs of DR, AMD, and Glaucoma

How does iCare Screening Solution work?

The AI detects early signs of diabetic retinopathy, AMD and glaucoma instantly and classifies the results according to severity based on international classifications. This allows healthcare professionals to focus on patients who are most in need of specialized care.

With iCare Screening Solution, you benefit from efficient processing for higher throughput and reliable results that match the level of a professional human grader.

 

Get a report with severity scoring

The iCare Screening Solution uses iCare RETCAD AI deep learning technology to analyze the fundus images captured by iCare DRSplus and generates a patient report with severity scoring for AMD and DR based on international standards (ICDR, AREDS). For glaucoma (GLC), the AI will indicate whether there is a glaucoma suspicion.

The report contains

1. Scores for AMD and DR indicating the severity of the disease and for GLC the AI will indicate whether there is a glaucoma suspicion

2. In cases where needed, recommendations to refer patients for further testing

3. Heatmaps highlighting bright and red lesions

4. Quality assessment of the input images

1/3

Diabetic retinopathy

DR is the leading cause of vision loss in adults aged 20–74 years. Over one-third of an estimated 285 million people worldwide with diabetes show signs of DR. DR is on the rise due to the increasing prevalence of diabetes, the aging population, and the increasing life expectancy of those with diabetes.

Age-related macular degeneration

AMD is a progressive, incurable disease, leading to severe visual impairment. It affects an estimated 170 million individuals worldwide and is one of the leading causes of visual disability. High prevalence makes periodic screening crucial to prevent the growing healthcare burden.

Glaucoma

Glaucoma is a chronic, degenerative, and irreversible disorder of the optic nerve that causes visual field damage. It affects an estimated 80 million people worldwide, making it the second leading cause of blindness globally. Periodic testing enables early diagnosis and helps prevent visual disability.

  • Interested?

    Local qualified iCare distributors are ready to help you with all matters related to iCare products and services.

    Contact us

  • Product materials

    Get support materials for your iCare products by filling in the form.

    Material request

iCare Screening Solution